Real Pharma India Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 3.60 M
- Company Age 28 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 18.62%
- Profit Growth 19.82%
- Ebitda -12.15%
- Net Worth 4.55%
- Total Assets 4.51%
About Real Pharma India
Real Pharma India Private Limited (RPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 July 1996 and has a history of 28 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.60 M, as per Ministry of Corporate Affairs (MCA) records.
Ananya Singh and Anil Prakash serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH1996PTC101322
- Company No.
101322
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Real Pharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ananya Singh  | Director | 01-Dec-2022 | Current |
| Anil Prakash | Director | 20-Jun-2021 | Current |
Financial Performance of Real Pharma India.
Real Pharma India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.62% increase. The company also saw a substantial improvement in profitability, with a 19.82% increase in profit. The company's net worth moved up by a moderate rise of 4.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Real Pharma India?
In 2023, Real Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Principle Security And Allied Services Private LimitedAnil Prakash is a mutual person
Risk Care Insurance Broking Services Private LimitedAnil Prakash is a mutual person
Sal Technologies & Solutions LimitedAnanya Singh and Anil Prakash are mutual person
- Sal Comm Trades Private Limited
Ananya Singh is a mutual person
- Sal Securities Private Limited
Ananya Singh is a mutual person
- Carbide (Asia) Pvt Ltd
Anil Prakash is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Real Pharma India?
Unlock and access historical data on people associated with Real Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Real Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Real Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
